IL1B and neoplasm: No correlation was observed between tumour mutational load (TMB) and homologous recombination deficiency (HRD) (Figures 4E-M), suggesting that IL-1 signalling acts mainly by enhancing the anti-tumour function of immune cells and has little effect on the tumour cells themselves.